HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Samaras, P. Articles by Knuth, A. Search for Related Content PubMed PubMed Citation Articles by Samaras, P. Articles by Knuth, A.

Treatment of POEMS syndrome with bevacizumab

Department of Oncology, University Hospital Zurich, Switzerland

Correspondence: Panagiotis Samaras, University Hospital Zurich, Department of Oncology, Ramistrasse 100, 8091 Zurich, Switzerland. Phone: international +41.044.2552214. Fax: international +41.044.2554548. E-mail: panagiotis.samaras{at}usz.ch

We report a case of POEMS syndrome which relapsed six years after autologous peripheral blood stem cell transplantation. According to encouraging data published recently, we treated the patient with cyclophosphamide, dexamethasone and the VEGF-antibody bevacizumab. After an initial improvement, the subsequent course was complicated by severe adverse events leading to multiorgan failure and death. This dramatic decline highlights the need for further investigation before using bevacizumab in patients with POEMS syndrome.

Key words: POEMS, pulmonary hypertension, plasma cell, VEGF, bevacizumab.